

Reviewing the answers against the FINMA Circular 2016/5 regarding how insurance companies should manage and report structured product investments:

## **Answer 1 Analysis:**

- 1. Relevance: Discusses general management strategies, aligns with the need for a strategic approach.
- 2. Accuracy: General statements about management and reporting are accurate but lack specific reference to structured products as per FINMA guidelines.
- 3. Completeness: Provides a comprehensive overview of management practices and reporting requirements, though it misses specific details about structured products.
- 4. Clarity: Clearly written, but does not provide specific guidelines from FINMA regarding structured products.

Score: 5/10 - While the answer provides a general framework for management and reporting, it lacks specific references to structured products as detailed in the FINMA Circular.

## **Answer 2 Analysis:**

- 1. Relevance: Directly addresses structured products and outlines specific management and reporting guidelines.
- 2. Accuracy: Accurately reflects the contents of the FINMA Circular regarding the management of structured products, including complian  $\langle \downarrow \rangle$  nd risk management aspects.
- Completences Covers constituted and compliance visit accessors and the enceille